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Objective: The objective of this study was to determine
the cost-effectiveness of thromboprophylaxis with enoxa-
parin versus no thromboprophylaxis in patients with
acute medical illness in Spain from the society perspec-
tive.
Methods: Markov process analysis techniques were used
to model the health economic outcomes. Clinical data
were derived mainly from the MEDENOX trial, while
health-care utilization was derived from Delphi panels.
Results: An analysis over the MEDENOX trial period
shows that the cost per event avoided is €432, while the
cost per life saved is €1527. The cost per event includes
all medical resource utilization costs associated with the
event. The lifetime model, which assumes no higher risk
for recurrence of venous thromboembolism (VTE) and
mortality in asymptomatic patients, shows that the use 
of enoxaparin leads a cost per event avoided of €270 
and cost per life-year gained of €71. If the lifetime model
assumes a higher risk for recurrence of VTE in asympto-
matic patients, enoxaparin is dominant over no 
thromboprophylaxis.
Conclusion: The results showed that the favorable clini-
cal beneﬁt of enoxaparin as thromboprophylaxis in
patients with acute medical illness, which was observed
in the MEDENOX trial, results in a positive health eco-
nomic beneﬁt in both the short term and the long term in
the health-care setting of Spain.
Keywords: cost-effectiveness, enoxaparin, Markov
model, Spain.
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ABSTRACT
Introduction
Clinical Background
Venous thromboembolism (VTE) is a complex vas-
cular disease with a multifactorial pathogenesis and
has two major clinical manifestations. The most
common one is the deep venous thrombosis (DVT),
which usually arises in the deep veins of the calf and
spreads upward. The other and more serious man-
ifestation is the pulmonary embolism (PE), which
might be life-threatening. The long-term conse-
quences of DVT are the recurrences of VTE events
and the development of post-thrombotic syndrome
(PTS), of which common manifestations are vari-
cose veins, ulceration of the legs, and pain.
Epidemiology
There are no reliable epidemiologic studies on VTE
in Spain. Nevertheless, we found data that allow us
to estimate the prevalence and/or incidence of VTE.
It is estimated that there are 660,000 cases per year
of VTE in Spain, 600,000 of which are DVT and
60,000 of which are PE [1,2]. According to data
from the National Institute of Statistics, in 1997 a
total of 14,263 patients were hospitalized with VTE
and 38,030 were hospitalized with varicose veins in
the lower limbs [3]. According to data from the
same source, in 1996 a total of 965 deaths were
noted, whose direct cause was VTE [4]. However,
some authors estimate that the ofﬁcial statistics
underestimate the deaths really caused by VTE,
ranging from 6,000 to 23,000 [1,2,5].
PE, the second and more serious manifestation
of VTE, occurs as a complication of VTE proximal
to the deep calf veins. A study by Moser and
coworkers [6] showed that nearly 40% of patients
with DVT but no symptoms of PE had evidence of
PE on lung scanning. Those ﬁnding correspond with
a Spanish study, which reports that 41% of patients
with DVT had silent PE [7]. Another Spanish study
showed that the prevalence of DVT in patients with
PE is estimated to be 83% [8]. Fatal and nonfatal
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embolisms are most often clinically silent with the
disease being unsuspected before death in 70% to
80% of the patients [9]. Extrapolation of data from
meta-analyses suggests that fatal PE occurs in 0.5%
to 0.8% of patients over the age of 40 undergoing
major abdominal surgery [10]. The mortality rate
for PE is rather high; for example, in a US study,
the 3-month mortality rate was found to be 17.5%
[11]. Another study mentions an overall mortality
of 20% due to the development of a PE [12].
The Long-Term Complications of VTEs
Recurrences. A study by Prandoni et al. [13]
reported a 17.5% cumulative incidence of recur-
rence during the ﬁrst 2 years and 30.3% during 8
years follow-up in patients who had symptomatic
DVT. Grau et al. [14] reported that the cumulative
incidence of recurrent VTE after 2, 5, and 10 years
was 7, 8, and 12.4%, in a Spanish population,
respectively. Bergqvist et al. [15] performed a 15-
year retrospective study comparing two cohorts
(patients with a history of a VTE and controls). At
study entry, the mean age was 64 years in the
thrombosis group (60% men) and 66 years in the
controls (59% men). This study yielded annual data
on recurrence rates for patients with a history of
VTE and mortality, which were substantially higher
than the incidence and mortality of the controls.
After 15 years of follow-up, 35% of the patients
with thrombosis and 57% of the controls were
alive. The recurrence rates included the following
events: DVT, PE, PTS, PTS infection and varicosis,
and combinations of several conditions. Table 1
shows the recurrence rates, which show already
after the ﬁrst year a substantial difference: 39.03
versus 2.16%. The cumulative incidences after 15
years were, respectively, 57.26 and 13.10% for the
study population and the controls.
The above-mentioned studies by Prandoni et al
[13] and Bergqvist et al. [15] are based on patients
with a symptomatic VTE only. No data exist for
recurrence of VTE events for patients who experi-
enced an asymptomatic VTE, although the clinical
experts who participated in this study all indicate 
a higher risk compared with patients without a 
previous VTE.
PTS. The PTS is probably caused by a combination
of venous hypertension, resulting from persisting
venous obstruction, venous valve damages, and
abnormal microcirculation [16]. A study by
Monreal et al. [17] showed that 56% of patients
with DVT developed PTS during a 3-year follow-
up period. Two-thirds of patients had mild PTS
signs and one-third had severe ones. The study by
Prandoni et al. [13] mentions that the cumulative
incidence of PTS was 22.8% after 2 years, 28%
after 5 years, and 29.1% after 8 years.
Prophylaxis. The MEDENOX clinical trial was
the ﬁrst study to demonstrate the efﬁcacy and safety
of thromboprophylaxis in patients with acute
medical illnesses, who may be at risk for VTE (Table
2) [18]. The incidence of VTE events was signiﬁ-
cantly lower in the group of patients who received
40 mg of enoxaparin than in the placebo group (5.5
and 14.9%, respectively; relative risk, 0.37; P <
.001). The beneﬁt observed with 40 mg of enoxa-
parin was maintained at 3 months: by day 110, 
the ﬁgures were 7.0 versus 17.1%. The incidence of
Table 1 Recurrence and mortality rates for symptomatic VTE (post-MEDENOX period)
Recurrence rate Mortality rate
History of No history of History of No history of 
Year symptomatic VTE symptomatic VTE symptomatic VTE symptomatic VTE
1 0.3903 0.0216 0.1128 0.0373
2 0.1238 0.0089 0.0701 0.0332
3 0.1117 0 0.0506 0.0332
4 0.0765 0.0291 0.0544 0.0415
5 0.1023 0.005 0.0273 0.0249
6 0.0614 0.0105 0.0506 0.0415
7 0.0629 0.016 0.0156 0.0083
8 0.0946 0.0057 0.0432 0.0581
9 0.1121 0 0.0198 0.0249
10 0.0363 0 0.0201 0.0125
11 0.032 0.0129 0.0494 0.0373
12 0.0444 0 0.0473 0.0124
13 0.0397 0 0.0467 0.0374
14 0.053 0.014 0.025 0.0083
15 0 0.0073 0.0155 0.0166
Note: Represents annual values. Derived from Bergqvist et al. [15].
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adverse events was not statistically different
between the placebo and the enoxaparin group. The
results of the MEDENOX trial are summarized in
Table 3.
The favorable effect of enoxaparin on the reduc-
tion of acute VTEs and the reduction of long-term
recurrence of VTEs may mean that enoxaparin is a
cost-effective therapy. The present study uses a mod-
eling technique to estimate the cost-effectiveness of
thromboprophylaxis with enoxaparin versus no
thromboprophylaxis in Spain. The objective of this
study was to generate estimates of the costs and cost-
effectiveness of thromboprophylaxis with enoxa-
parin versus no thromboprophylaxis (usual care) in
patients with acute medical illness in the health-care
setting of Spain.
Materials and Methods
To estimate the costs and effectiveness of thrombo-
prophylaxis with enoxaparin versus no thrombo-
prophylaxis in the health-care setting of Spain, a
lifetime model was constructed using decision
analysis techniques [19,20]. The main analytical
plan for the study was an incremental cost-
effectiveness analysis. This approach consists of
combining cumulative measures of costs over time
with a cumulative measure of effectiveness, result-
ing in incremental costs per clinical beneﬁt gained
(e.g., cost per life-year gained, cost per event
avoided, and cost per life saved). The analysis was
performed for a hypothetical cohort of 65-year-olds
who were considered to be at moderate risk for
venous thromboembolic events and who had been
hospitalized with an acute medical illness. In
general, the inclusion criteria of the MEDENOX
trial were used. Because the MEDENOX clinical
trial showed no signiﬁcant difference between 20
mg of enoxaparin and placebo, the economic eval-
uation was restricted to a 40 mg of enoxaparin
versus placebo comparison. Effectiveness was
expressed as VTE events, mortality, and life
Table 2 Baseline characteristics of study populations in the MEDENOX trial
Characteristic Placebo (n = 371) 40 mg enoxaparin (n = 367)
Mean age (years) 74.1 ± 10.6 73.1 ± 10.8
Sex (M/F) 192/178 171/196
Reason for hospitalization, No. (%)
NYHA class III CHF 95 (25.7) 103 (28.1)
NYHA class IV CHF 32 (8.6) 26 (7.1)
Acute respiratory failure 202 (54.6) 195 (53.1)
Acute infectious disease 193 (52.2) 197 (53.7)
Acute rheumatic disorder 32 (8.6) 28 (7.6)
Inﬂammatory bowel disease 1 (0.3) 3 (0.8)
Table 3 Transition probabilities for Cycle 1 (MEDENOX period)
Deﬁnition Enoxaparin (40 mg) Placebo Source
Probability of VTE MEDENOX trial, Samama et al. [18]
Enoxaparin 0.0699
19/272
Usual care 0.1711
45/263
Probability of symptomatic VTE MEDENOX trial, Samama et al. [18]
Enoxaparin 0.2632
5/19
Usual care 0.1556
7/45
Probability of mortality MEDENOX trial, Samama et al. [18]
Enoxaparin 0.1139
41/360
Usual care 0.1381
50/362
Distribution of PE and DVT MEDENOX trial, Samama et al. [18]
DVT VS. PE weights among those with symptomatic VTE
% with DVT 0.60 0.57
% with PE 0.40 0.43
3/5 4/7
Note:This table is based on the MEDENOX trial data.The placebo data were used for the no thromboprophylaxis arm (usual care) in the model.We indicated
for each probability the actual numbers on which the calculation was based. For instance, the probability of mortality for usual care (0.1381) was based on 49
patients of 362 who died during the MEDENOX period.
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expectancy; the model also included all relevant
economic measures. These included resource uti-
lization patterns associated with outpatient and
inpatient care for the treatment of VTE events,
which were classiﬁed as PE, DVT, and PTS. The
setting of the study was that of the Spanish health-
care system of 2001; the perspective of the study
was that of the society. The costs were discounted
at 5% from the second year onward; we did not
apply discounting in the ﬁrst year. The data sources
were literature, including the MEDENOX trial, the
Delphi panel, and ofﬁcial price and tariff lists.
External clinical opinion leaders validated the
methodology (model structure and assumptions).
A health economic model was chosen for several
reasons to assess the cost-effectiveness of enoxa-
parin. The existing cost-effectiveness data for
enoxaparin in France and the United Kingdom
cannot be extrapolated to Spain because of differ-
ences in underlying treatment patterns, health-care
ﬁnancing systems, and prices/tariffs. In addition, the
existing health economic studies only assessed the
short-term health economic beneﬁts not taking into
account the long-term favorable clinical conse-
quences of the use of enoxaparin: reduction of
short-term VTEs may be associated with short-
term, but also long-term, health economic beneﬁts.
In contrast to economic data, clinical trial data of
the MEDENOX trial could be extrapolated to the
Spanish health-care setting, because clinical data in
most diseases can be considered not to be country-
speciﬁc [21]. External clinical opinion leaders
agreed with this assumption for VTEs.
Description of the Model
Figure 1 shows the structure of the Markov 
model for VTE. The model structure for the “no
thromboprophylaxis” treatment arm is identical to
the thromboprophylaxis treatment arm. For this
analysis we initially deﬁned the following Markov
states:
• MEDENOX: the inpatient and postdischarge
follow-up period (3 months) in the MEDENOX
clinical trial;
• Remainder-VTEsymp: the follow-up period
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Figure 1 Structure of the Markov model.
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beyond the 3-month MEDENOX clinical trial
period for patients who had a symptomatic VTE
during the MEDENOX trial period;
• Remainder-VTEasymp: the follow-up period
beyond the 3-month MEDENOX clinical trial
period for patients who had an asymptomatic
VTE during the MEDENOX trial period;
• Remainder-no VTE: the follow-up period
beyond the 3-month MEDENOX clinical trial
period for patients who did not have a VTE
(symptomatic or asymptomatic) during the
MEDENOX trial period;
• Dead.
In the model, all patients begin in the state
MEDENOX due to an underlying disease. Hence,
this state does not represent hospitalization due 
to a VTE (DVT and/or PE). Patients with a VTE
during the initial MEDENOX period may have a
symptomatic or asymptomatic VTE.
• Patients with a symptomatic VTE who survive
go to “Remainder-VTEsymp” for Cycle 2.
• Patients with an asymptomatic VTE who
survive go to “Remainder-VTEasymp” for Cycle
2.
• Patients without a VTE go to “Remainder-
noVTE” for Cycle 2.
Note that all the “VTE’s” after the MEDENOX
period refer to “symptomatic VTE” because infor-
mation on “asymptomatic VTE” was unavailable 
in the existing literature. After the MEDENOX
period, all patients have annual probabilities of
recurrent VTE or mortality, which differ for each
health state. The difference between the health
states “Remainder-VTEsymp” and “Remainder-
noVTE” is that the probability of the development
of a VTE is higher in patients in the health state
“Remainder-VTE symp.” Stratiﬁcation into these
health states is required because patients with a
history of a symptomatic VTE will have higher life-
time probabilities of VTE events, which also may
be associated with different treatment patterns (pre-
ventive treatment); patients with symptomatic
VTEs are associated with a higher annual mortal-
ity. In contrast, patients without a history of VTE
will only develop a PE or DVT unrelated to the
initial VTE. In addition, the clinical expert indicated
that patients with an asymptomatic VTE also have
higher lifetime probabilities of VTE events, which
was conﬁrmed by other clinical experts in Spain.
Because the literature data did not yield any quan-
titative information on the risk of recurrence for
asymptomatic VTE, we applied two scenarios: 1)
patients with an asymptomatic VTE have no higher
risk of recurrence and mortality than patients
without a history of a symptomatic VTE; and 2)
patients with asymptomatic VTE have the same 
risk of recurrence and mortality as patients with a
history of a symptomatic VTE and consequently
also a higher mortality risk.
For Cycles 2 and beyond, the data from Bergqvist
et al. [15] provide estimated recurrence rates of
VTEs in persons with and without previous symp-
tomatic VTEs (Table 1). Comparisons of the tran-
sition probabilities in Table 1 show that patients
with a history of symptomatic VTE have higher 
lifetime probabilities of VTE events. Table 1 also
shows that those patients also have higher mortal-
ity risks. In addition, the data by Bergqvist et al.
[15] provided information on the distribution 
for the various VTE events (DVT, PE, and PTS)
(Table 4).
Various follow-up times were considered in the
model:
1. MEDENOX trial period: An analysis was
based on a follow-up time (analytical horizon)
that corresponded with the period of hospital-
ization—the inpatient hospital phase of the
MEDENOX trial (i.e., days 1–14) plus the
remainder patient follow-up period (i.e., days
15–90) of the MEDENOX trial. These were
combined as the lack of adequate numbers of
DVT and PE events in each arm during the
inpatient phase alone made separate analysis
for hospitalization impractical.
2. A 1-year period corresponding with annual
budgets.
Table 4 Distribution of PE, DVT, and PTS (post-MEDENOX
period)
Deﬁnition Value Source
Inpatient/ambulatory MEDTAP 
Hospitalized survey
DVT 0.800
PE 1.000
PTS 0.108
PTS infection without varicosis 0.100
VAR treatment of varicosis 0.055
Recurrent events
Distribution of DVT, PE, and PTS Bergqvist 
PE 0.135 et al. [15]
DVT 0.502
PTS 0.288
Combined 0.075
Note: This table shows the distribution between ambulatory treatment (out-
patient care) and hospitalization (inpatient care) for VTE events, which was
based on the estimations by the Delphi panel, and the distribution between
various VTE events (PE, DVT, PTS, and combined VTE events) after the
MEDENOX trial period.Those data were derived from the study by Bergqvist
et al. [15]. (Table 3 shows the distribution of VTE events during the MEDENOX
trial period.)
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3. A 5-year period.
4. A 10-year period.
5. A lifetime period.
The model was based on the assumption that the
study population in the MEDENOX trial corre-
sponds with the patients in the study by Bergqvist
et al. [15] with regard to the recurrence of VTEs
and annual mortality risk. Another previously men-
tioned assumption was that the clinical data of the
MEDENOX trial could be applied to patients in
Spain.
Clinical and Economic Outcomes
Effectiveness. The primary efﬁcacy outcomes were
the number of VTE episodes clinically identiﬁed
between day 1 and day 110 (MEDENOX trial
data). The primary efﬁcacy outcomes were the 
input variables of the model, which extrapolated
those efﬁcacy data to various effectiveness out-
comes.
• Mortality rate;
• Number of VTEs;
• Life-years gained (lifetime model only).
Cost assessment. The model concentrated on all
relevant economic factors. These included resource
utilization measures of outpatient and inpatient
care for treatment of VTE events. Direct medical
costs were analyzed through physical units of health
care resources expended. An event-driven approach
was used to determine the costs of thrombopro-
phylaxis with enoxaparin versus standard therapy
in the deﬁned study population (hospitalized med-
ically ill patients considered to be at medium risk
for venous thromboembolic events). The clinical
events were the venous thromboembolic events
associated with enoxaparin and standard therapy:
VTE events (PE, DVT, and PTS) and costs associ-
ated with thromboprophylaxis with enoxaparin
(extra drug but also associated costs, e.g., extra con-
sultations and diagnostic tests).
Data Sources
Probabilities:
• MEDENOX trial period: The probabilities for
symptomatic and asymptomatic VTE events (PE
and DVT) and mortality during the ﬁrst 3
months were derived from the MEDENOX trial
(Table 3) [18].
• The mean age in the MEDENOX trial was 73.5
years, while the mean age in the study by
Bergqvist et al. [15] was 65 years. We decided
to use the average age of 65 years in the base
case analysis, because long-term mortality rates
and recurrence rates were directly derived from
the study by Bergqvist et al. [15]. The mortality
rates for the patients with and without VTE
were derived from the 15-year follow-up period
for, respectively, the patient population and the
controls. Life expectancy beyond this period
was based on OECD country-speciﬁc general
population mortality for Spain.
• The recurrence rates of VTE (DVT, PE, and PTS)
were derived from data in the Bergqvist et al.
15-year retrospective study [15]. This study pro-
vided rates of recurrent DVT, PE, and PTS in
patients with previous VTEs and rates of occur-
rence of VTE events in an age- and gender-
matched control group without initial VTE
(Table 1).
• The pooled data by Bergqvist et al. [15] provided
information on the distribution for the various
VTE events (DVT, PE, and PTS) (Table 4).
Resource utilization and costing. Data on
health-care utilization associated with the country-
speciﬁc treatment patterns were derived from a
panel of clinical experts in Spain (n = 8). The
resource utilization data was converted to cost data
(Tables 5–7) by applying relevant country-speciﬁc
unit costs. In addition, the Delphi panel provided
information on the distribution for the treatment
setting (inpatient vs. outpatient) of the various VTE
events (Table 4). Costing information consisted of
Table 5 Costs in Euros for PE (based on Delphi panel)
Cost Mean Q1 Q2
Hospitalization
Hospitalization costs after initial hospitalization 2044 1775 2835
Hospitalization costs during initial hospitalization 1389 1083 2306
Medication costs 42 4 81
Consultation costs 340 174 626
Procedure costs 291 37 420
Follow-up 778 330 1283
Prevention costs (monthly)
Total costs 305 62 534
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actual costs and prices or tariffs and was obtained
from ofﬁcial price and tariff lists in Spain. Costs are
expressed in Euros (1 € = 0.9219 US$).
Results
Each analysis has been performed twice to assess
the impact of the risk of recurrence for patients with
an asymptomatic VTE (Table 8). In the ﬁrst analy-
sis (no-risk scenario), we assumed no higher risk for
recurrence of VTE and mortality for patients who
experienced an asymptomatic VTE during the
MEDENOX trial; in a second analysis (risk sce-
nario), we assumed a higher risk for recurrence 
of VTE and mortality for those patients: the risk 
is similar to patients with symptomatic VTE. In 
addition, we assessed the impact of initial age of 
the population on the health economic outcomes
(Table 9).
Follow-Up of MEDENOX Trial Period and 
1 Year Later
An analysis over the MEDENOX trial period shows
that the cost per event avoided is €432 (US$398),
while the cost per life saved is €1527 (US$1408).
An extrapolation to 1 year shows that cost per 
event avoided is €332 (US$306) and cost per life
saved is €1212 (US$1117), when assuming no
higher risk for morbidity and mortality in asymp-
tomatic patients. Enoxaparin becomes dominant
over usual care, when assuming a higher risk for
recurrence of VTE and mortality in asymptomatic
patients.
Table 6 Costs in Euros for other VTE events (based on Delphi panel)
Cost Mean Q1 Q3
DVT
Hospitalization
Hospitalization costs after initial hospitalization 1981 1538 1987
Hospitalization costs during initial hospitalization 0 0 0
Medication costs 47 4 37
Consultation costs 304 16 239
Procedure costs 482 80 941
Follow-up 680 34 1522
Ambulatory costs
Total costs 638 124 980
Prevention costs (monthly)
Total costs 464 38 819
PTS
Hospitalization
Hospitalization costs 1548 705 3066
Medication costs 60 11 91
Consultation costs 327 86 529
Procedure costs 446 223 703
Follow-up 634 204 875
Ambulatory costs
Total costs 614 222 819
PTS infection without ulcus
Hospitalization
Hospitalization costs 547 143 1291
Medication costs 27 24 30
Consultation costs 244 148 352
Procedure costs 128 61 212
Follow-up 342 163 543
Ambulatory costs
Total costs 435 322 637
Varicosis
Hospitalization
Hospitalization costs 191 191 191
Medication costs 2 0 0
Consultation costs 83 83 83
Procedure costs 72 72 72
Follow-up 1270 224 1929
Ambulatory costs
Total costs 485 198 814
Table 7 Costs in Euros for thromboprophylaxis (based on
Delphi panel)
Cost Mean Q1 Q3
Medications 32 8 17
Consultations 24 0 0
Procedures 5 0 0
Nursing 9 1 9
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Follow-Up of 5 and 10 Years
The cost per event avoided is €296 (US$273) and
€271 (US$250) over, respectively, a follow-up
period of 5 and 10 years. The cost per life saved 
is, respectively, €1174 (US$1082) and €1283
(US$1183), when assuming no higher risk for mor-
bidity and mortality in asymptomatic patients.
Enoxaparin becomes dominant over usual care,
when using the risk for symptomatic patients for
recurrence of VTE and mortality.
Lifetime Follow-Up
The lifetime model, which assumes no higher risk
for recurrence of VTE and mortality in asympto-
matic patients, shows that the use of enoxaparin
leads to a cost per event avoided of €270 (US$249)
and cost per life-year gained of €71 (US$65). The
lifetime model, which assumes a higher risk for
recurrence of VTE in asymptomatic patients, shows
that enoxaparin is dominant over no thrombopro-
phylaxis.
Table 9 shows that the results of the lifetime cost-
effectiveness analysis depend on the initial age of
the patient. The cost per life-year gained decreases
from €71 (US$65) to €27 (US$25), when assuming
no higher risk for recurrence of VTE in asympto-
matic patients aged 40 years. The lifetime model,
which assumes a higher risk for those patients
Table 8 Health economic results over the various follow-up periods
Costs (Euros) Mortality Life expectancy (years) VTE events (#)
90 days
Enoxaparin 137 0.114 0.062
Usual care 100 0.138 0.147
Difference 37 –0.024 –0.086
ICR* 1527 NA 432
1 year-asymp = NR†
Enoxaparin 242 0.140 0.086
Usual care 213 0.164 0.173
Difference 29 –0.024 –0.087
ICR 1212 332
1 year-asymp = R‡
Enoxaparin 308 0.141 0.101
Usual care 392 0.170 0.213
Difference –84 –0.029 –0.113
ICR Dominant Dominant
5 years-asymp = NR
Enoxaparin 351 0.223 0.113
Usual care 325 0.246 0.201
Difference 26 –0.022 –0.088
ICR 1174 296
5 years-asymp = R
Enoxaparin 455 0.229 0.138
Usual care 610 0.262 0.267
Difference –155 –0.032 –0.130
ICR Dominant Dominant
10 years-asymp = NR
Enoxaparin 474 0.336 0.150
Usual care 450 0.355 0.238
Difference 24 –0.019 –0.089
ICR 1283 271
10 years-asymp = R
Enoxaparin 616 0.341 0.185
Usual care 836 0.369 0.335
Difference –220 –0.028 –0.150
ICR Dominant Dominant
Lifetime-asymp = NR
Enoxaparin 572 14.87 0.199
Usual care 548 14.53 0.288
Difference 24 0.34 –0.089
ICR 71 270
Lifetime-asymp = R
Enoxaparin 734 14.72 0.244
Usual care 990 14.14 0.411
Difference –256 0.59 –0.167
ICR Dominant Dominant
*ICR, incremental cost-effectiveness ratio: 1) cost per life gained (column “mortality”); 2) cost per life-year gained (column “life expectancy”); and 3) cost per VTE
event (column “VTE events”). Bold denotes avoided.
†asymp=NR, analysis assuming no higher risk for recurrence VTE and mortality for patients with an asymptomatic VTE.
‡asymp=R, analysis assuming a higher risk for recurrence VTE and mortality for patients with an asymptomatic VTE: risk is similar to patients with symptomatic
VTE. (This statement applies to all subsequent tables.)
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shows that enoxaparin remains dominant, but that
the cost savings increase from €256 (US$236) to
€282 (US$260). However, the cost per life-year
gained increases to €259 (US$239), when assuming
no higher risk for recurrence of VTE in asympto-
matic patients aged 73.5 years.
Sensitivity Analysis
Tables 10 and 11 present the results of the sen-
sitivity analyses. The various one-way sensitivity
analyses examined the sensitivity of the cost per
VTE event avoided to variance in the input variable.
We examined the sensitivity of the outcomes to 
speciﬁc probabilities related to enoxaparin (pro-
bability of VTE, probability of symptomatic VTE,
and mortality) during the MEDENOX trial and
data derived from the study by Bergqvist et al. [15]
(recurrence of a VTE and mortality). The ranges of
the speciﬁc probabilities related to enoxaparin were
based on the 90% conﬁdence interval (CI), except
for the distribution of events. Because of the small
number of events, we did not use a 90% CI, but
changed the probability of pulmonary embolus
between 0 and 100%. The sensitivity analyses for
the data from the study Bergqvist et al. [15] were
based on ﬁxed annual rates for each event (recur-
rence or mortality) instead of the real annual data
from Table 1. The minimum and maximum values
were, respectively, based on the ﬁrst and third 
quartiles for the annual probabilities in Table 1. 
The costs of PE, DVT, PTS, and thromboprophy-
laxis were varied between their ﬁrst and third 
quartiles. The time horizon was restricted to a 10-
year period.
Table 9 Lifetime cost-effectiveness analyses varying the initial age of the population
Costs (Euros) Mortality Life expectancy (years) VTE events (#)
40 years-asymp = NR
Enoxaparin 647 32.57 0.307
Usual care 624 31.72 0.396
Difference 23 0.85 –0.089
ICR 27 258
40 years-asymp = R
Enoxaparin 824 32.25 0.372
Usual care 1106 30.85 0.574
Difference –282 1.4 –0.202
ICR Dominant Dominant
73.5 years-asymp = NR
Enoxaparin 546 12.21 0.182
Usual care 523 11.95 0.271
Difference 23 0.26 –0.089
ICR 88 259
73.5 years-asymp = R
Enoxaparin 704 12.11 0.225
Usual care 955 11.68 0.388
Difference –251 0.43 –0.163
ICR Dominant Dominant
Table 10 Results of sensitivity analysis for the various input
variables of the model: no higher risk for asymptomatic
patients
Cost (Euros) 
per VTE 
Variable event avoided
Probability of VTE (enoxaparin) Dominant–1106
Probability of symptomatic VTE (enoxaparin) Dominant–1244
Mortality (enoxaparin) 110–450
Probability of PE (distribution of events) 127–291
Recurrence in symptomatic patients 178–312
Recurrence in asymptomatic patient 183–216
Mortality in symptomatic patients 64–288
Mortality in asymptomatic patients 67–278
Cost of PE 231–293
Cost of DVT 236–302
Cost of PTS 266–273
Thromboprophylaxis–drugs 232–202
Thromboprophylaxis–other 223–287
Table 11 Results of sensitivity analysis for the various input
variables of the model: higher risk for asymptomatic patients
Cost (Euros) 
per VTE 
Variable event avoided
Probability of VTE (enoxaparin) Dominant
Probability of symptomatic VTE (enoxaparin) Dominant
Mortality (enoxaparin) Dominant
Probability of PE (distribution of events) Dominant
Recurrence in symptomatic patients Dominant
Recurrence in asymptomatic patient Dominant
Mortality in symptomatic patients Dominant
Mortality in asymptomatic patients Dominant
Cost of PE Dominant
Cost of DVT Dominant
Cost of PTS Dominant
Thromboprophylaxis–drugs Dominant
Thromboprophylaxis–other Dominant
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The sensitivity analyses (Table 10) for the
MEDENOX trial period and the lifetime model,
which assume no higher risk for recurrence of VTE
in asymptomatic patients, show that variances in
probabilities related to enoxaparin are the most sen-
sitive variables. The model is not very sensitive to
the cost of PE, DVT, and drugs for thrombopro-
phylaxis. Nevertheless, all cost-effectiveness out-
comes may be justiﬁed from a health economic
perspective, and consequently the conclusion of this
study that enoxaparin is cost-effective is not
affected by the variance in the various costs.
The sensitivity analysis (Table 11), which
assumes a higher risk for recurrence of VTE in
asymptomatic patients, shows that the model is very
robust to variance in costs: enoxaparin remains
dominant versus no thromboprophylaxis in all sen-
sitivity analyses.
Discussion and Conclusion
This study has examined the costs and cost-
effectiveness of thromboprophylaxis with enoxa-
parin versus no thromboprophylaxis (usual care) in
patients with acute medical illness in the health-care
setting of Spain. The analysis revealed that throm-
boprophylaxis with enoxaparin was cost-effective:
thromboprophylaxis with enoxaparin yields a
higher effectiveness in terms of effectiveness mea-
sures (mortality, life-years gained, and VTE events).
The additional drug costs for enoxaparin are offset
by reductions in other costs, especially hospitaliza-
tion. The results show that the health economic
beneﬁt of enoxaparin depends on the underlying
assumptions and time horizons. The health eco-
nomic beneﬁt of enoxaparin is positively related to
the length of the follow-up period, the assumption
of a higher risk for recurrence of VTE, and the mor-
tality for asymptomatic patients. In addition, this
study shows that the younger the patient, the more
profound the health economic beneﬁt of enoxaparin
becomes.
Only recently have cost-effectiveness results 
been published for acutely ill medical patients 
corresponding with the study population of the
MEDENOX trial. A study was performed by
Pechevis et al. [22] for the French health-care
setting, which was an economic evaluation of a
strategy of thromboprophylaxis in acutely ill
medical patients with 40 mg of enoxaparin versus
no intervention in the context of the French health-
care system. The evaluation used a decision analy-
sis model to simulate the results of a hypothetical
naturalistic, long-term study reﬂecting the usual
care pattern for the patients. The study by Pechevis
et al. [22] for the French health-care setting yielded
an incremental cost-effectiveness ratio in terms of
cost per death avoided, which did not exceed $7376
(€8102), while our study yielded a ﬁgure of €1527.
Another study by Lloyd et al. [23] assessed the cost-
effectiveness of prophylaxis for VTE in acutely ill
medical patients in the United Kingdom. The incre-
mental cost-effectiveness ratio for enoxaparin 
compared to no prophylaxis was €1260 per event
avoided, which is higher than the €432 in our study.
Overall, we may conclude that the results of this
study are more favorable than the previous pub-
lished cost-effectiveness studies. The differences
between the various studies may be due to the use
of different modeling methodologies. Another more
acceptable explanation is that the differences in
health-care utilization associated with the country-
speciﬁc treatment patterns favor the cost-
effectiveness of enoxaparin in Spain.
Given that there are some limitations to the mod-
eling technique, its advantages should also be
pointed out. The ideal design for demonstrating the
possible long-term health economic outcomes asso-
ciated with thromboprophylaxis with enoxaparin
would be a naturalistic prospective study, which
may require a follow-up of a period varying from 5
to 10 years from a health economic perspective,
which is not feasible. The use of a Markov model
allowed us to extrapolate clinical outcomes beyond
the duration of the existing clinical trials. Where we
felt that there was a question about the results, a
sensitivity analysis was performed. This can be seen
in the case of varying the recurrence rate of VTEs
in patients with an asymptomatic VTE event,
changing the initial age of the patient and costs for
VTE events and thromboprophylaxis.
The results of this study showed that thrombo-
prophylaxis with enoxaparin in patients with acute
medical illness may be justiﬁed from a health 
economic perspective. Thromboprophylaxis with
enoxaparin is not only associated with substantial
clinical beneﬁts (MEDENOX trial), but this study
also showed that the use of enoxaparin leads to
both short-term and long-term beneﬁcial health
economic beneﬁts for the patient as well as the
health-care system in Spain.
This study was supported by Aventis Pharma.
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